Papilloma Virus Vaccine Therapy in Treating Young Patients With Recurrent Papilloma of the Larynx
Launched by UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY · Feb 26, 2004
Trial Information
Current as of March 22, 2025
Unknown status
Keywords
ClinConnect Summary
OBJECTIVES: I. Determine the immune response in patients with juvenile papilloma of the larynx treated with autogenous vaccine derived from each patient's own tumor.
OUTLINE: Patients receive autogenous papilloma vaccine intradermally and subcutaneously weekly for 20 weeks.
PROJECTED ACCRUAL: Not specified
Gender
ALL
Eligibility criteria
- • DISEASE CHARACTERISTICS: Diagnosis of severe recurrent juvenile papilloma of the larynx requiring surgery at least 4 times per year Condition must have existed for more than 1 year
- • PATIENT CHARACTERISTICS: Age: 1 and over Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified
- • PRIOR CONCURRENT THERAPY: See Disease Characteristics
Trial Officials
James M. Oleske, MD
Study Chair
Rutgers, The State University of New Jersey
About University Of Medicine And Dentistry Of New Jersey
The University of Medicine and Dentistry of New Jersey (UMDNJ) is a prominent academic institution dedicated to advancing healthcare through education, research, and clinical practice. As a leading sponsor of clinical trials, UMDNJ leverages its comprehensive medical and dental programs to foster innovative research initiatives aimed at improving patient outcomes and enhancing medical knowledge. The university is committed to creating a collaborative environment that encourages interdisciplinary approaches, ensuring rigorous scientific methodologies and ethical standards in all its clinical research endeavors. Through its extensive network of healthcare professionals and state-of-the-art facilities, UMDNJ plays a vital role in the development of new therapeutic interventions and the translation of research findings into clinical practice.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Newark, New Jersey, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials